In-depth valuation analysis including DCF scenarios and peer comparisons.
AI Insight: Incyte’s current price aligns closely with its fair value, indicating fair valuation amid high confidence. Robust financial health contrasts with wide Monte Carlo volatility and significant downside risk (77.8%), signaling pronounced valuation uncertainty and potential investment risk. EV/EBITDA suggests upside opportunity, contrasting more conservative DCF and analyst targets.